StockData
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. (CTXR) stock

CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$0.51−0.01 (-1.56%)

Close on Nov 18, 2026Market cap $14.02MP/E –Yield –

Citius Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Citius Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$61.38M. For fiscal 2025 it was -$38.53M. The highest annual figure on record is -$19.62K in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$38.53M–
FY2024Sep 30, 2024-$42.00M–
FY2023Sep 30, 2023-$36.73M–
FY2022Sep 30, 2022-$33.32M–
FY2021Sep 30, 2021-$23.53M–
FY2020Sep 30, 2020-$17.71M–
FY2019Sep 30, 2019-$15.60M–
FY2018Sep 30, 2018-$13.79M–
FY2017Sep 30, 2017-$9.99M–
FY2016Sep 30, 2016-$7.45M–
FY2012Sep 30, 2012-$19.62K–
FY2011Sep 30, 2011-$25.64K–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$11.73M–
Q2 FY2026CQ1 2026Mar 31, 2026-$32.19M–
Q1 FY2026CQ4 2025Dec 31, 2025-$9.02M–
Q4 FY2025CQ3 2025Sep 30, 2025-$8.44M–
Q3 FY2025CQ2 2025Jun 30, 2025-$8.79M–
Q2 FY2025CQ1 2025Mar 31, 2025-$11.26M–
Q1 FY2025CQ4 2024Dec 31, 2024-$10.04M–
Q4 FY2024CQ3 2024Sep 30, 2024-$11.05M–
Q3 FY2024CQ2 2024Jun 30, 2024-$10.63M–
Q2 FY2024CQ1 2024Mar 31, 2024-$10.97M–
Q1 FY2024CQ4 2023Dec 31, 2023-$9.34M–
Q4 FY2023CQ3 2023Sep 30, 2023-$10.12M–
Q1 FY2023CQ4 2022Dec 31, 2022-$7.25M–
Q4 FY2022CQ3 2022Sep 30, 2022-$7.55M–
Q3 FY2022CQ2 2022Jun 30, 2022-$8.92M–
Q2 FY2022CQ1 2022Mar 31, 2022-$7.59M–
Q1 FY2022CQ4 2021Dec 31, 2021-$9.26M–
Q4 FY2021CQ3 2021Sep 30, 2021-$5.20M–
Q3 FY2021CQ2 2021Jun 30, 2021-$5.98M–
Q2 FY2021CQ1 2021Mar 31, 2021-$4.19M–
Q1 FY2021CQ4 2020Dec 31, 2020-$8.16M–
Q4 FY2020CQ3 2020Sep 30, 2020-$4.14M–
Q3 FY2020CQ2 2020Jun 30, 2020-$4.69M–
Q2 FY2020CQ1 2020Mar 31, 2020-$4.43M–
Q1 FY2020CQ4 2019Dec 31, 2019-$4.45M–
Q4 FY2019CQ3 2019Sep 30, 2019-$3.66M–
Q3 FY2019CQ2 2019Jun 30, 2019-$4.43M–
Q2 FY2019CQ1 2019Mar 31, 2019-$3.64M–
Q1 FY2019CQ4 2018Dec 31, 2018-$3.87M–
Q4 FY2018CQ3 2018Sep 30, 2018-$3.66M–
Q3 FY2018CQ2 2018Jun 30, 2018-$2.02M–
Q2 FY2018CQ1 2018Mar 31, 2018-$4.87M–
Q1 FY2018CQ4 2017Dec 31, 2017-$3.24M–
Q4 FY2017CQ3 2017Sep 30, 2017-$2.40M–
Q3 FY2017CQ2 2017Jun 30, 2017-$2.26M–
Q2 FY2017CQ1 2017Mar 31, 2017-$2.54M–
Q1 FY2017CQ4 2016Dec 31, 2016-$2.78M–
Q4 FY2016CQ3 2016Sep 30, 2016-$3.41M–
Q3 FY2016CQ2 2016Jun 30, 2016-$2.13M–

More Citius Pharmaceuticals figures

See a number that looks wrong?